<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01862939</url>
  </required_header>
  <id_info>
    <org_study_id>DS7309-A-U101</org_study_id>
    <nct_id>NCT01862939</nct_id>
  </id_info>
  <brief_title>A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Double Blind, Placebo-Controlled, Randomized, Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, 2-part, sequential, single ascending dose study.&#xD;
&#xD;
      Part 1 is planned as 6 sequential escalation treatment groups. Part 2 is a randomized,&#xD;
      placebo-controlled, two-period sequential pharmacodynamic (PD) arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incremental area under the curve (IAUC) blood glucose</measure>
    <time_frame>5 hours</time_frame>
    <description>The incremental area under the curve (IAUC) of the PD biomarker blood glucose following an oral glucose tolerance test (OGTT) in subjects with type 2 diabetes mellitus (T2DM).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine blood concentrations of DS-7309</measure>
    <time_frame>48 hours</time_frame>
    <description>The plasma pharmacokinetic (PK) parameters of A203-5319 (the free form of DS-7309) and relevant metabolite of DS-7309 in healthy subjects and subjects with T2DM.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>part 1 DS-7309 ascending dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1, 2.5, 5, 10, 20 mg blinded DS-7309 powder in bottle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>part 2 DS-7309</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1, 2.5, 5, and 15mg DS-7309 powder in bottle for oral solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>part 2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo to match part 2 DS-7309</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-7309</intervention_name>
    <description>1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.</description>
    <arm_group_label>part 1 DS-7309 ascending dose</arm_group_label>
    <arm_group_label>part 2 DS-7309</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo to match part 2 DS-7309</description>
    <arm_group_label>part 2 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women must be of non-child bearing potential, ie, either:&#xD;
&#xD;
               1. Surgically sterile (ie, bilateral tubal ligation or removal of both ovaries&#xD;
                  and/or uterus at least 6 months prior to dosing), or&#xD;
&#xD;
               2. Naturally postmenopausal (spontaneous cessation of menses) for at least 24&#xD;
                  consecutive months prior to dosing, with a follicle stimulating hormone (FSH)&#xD;
                  level at screening of ≥ 40 mIU/mL.&#xD;
&#xD;
          -  All women must have a negative serum pregnancy test at screening and within 48 hours&#xD;
             before dosing.&#xD;
&#xD;
          -  Able to understand and willing to comply with all study requirements, and willing to&#xD;
             follow the study medication regimen.&#xD;
&#xD;
          -  Subjects must give written informed consent to participation in the study prior to&#xD;
             screening.&#xD;
&#xD;
          -  Negative urine test for drugs of abuse and alcohol at screening and check-in.&#xD;
&#xD;
          -  Negative result for HIV antibody, hepatitis B surface antigen, and hepatitis C&#xD;
             antibody at screening.&#xD;
&#xD;
          -  Subjects must agree to abstain from alcohol, cola, tea, coffee, chocolate and other&#xD;
             caffeinated drink and food from 2 days before check-in and throughout confinement.&#xD;
&#xD;
          -  Subjects must agree to abstain from grapefruit/grapefruit juice and Seville oranges&#xD;
             from 10 days before the first dose and throughout the study.&#xD;
&#xD;
          -  Healthy women who are not of childbearing potential and men, 18 to 45 years of age,&#xD;
             inclusive.&#xD;
&#xD;
          -  Body Mass Index (BMI) of 19.00 to 32.00 kg/m2 inclusive.&#xD;
&#xD;
          -  Good health, as determined by the absence of clinically significant deviation from&#xD;
             normal, based on medical history, physical examination, laboratory reports, and&#xD;
             12-lead ECG, as deemed by the Investigator, prior to enrollment.&#xD;
&#xD;
          -  Baseline (0 hour) pre-dose capillary blood glucose ≥ 70 mg/dL. Part 2 (T2DM subjects)&#xD;
&#xD;
          -  Women who are not of childbearing potential and men, 18 to 55 years of age, inclusive.&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes mellitus for a minimum of 3 months prior to first dose.&#xD;
&#xD;
          -  Body Mass Index (BMI) of 19.00 to 40.00 kg/m2 inclusive.&#xD;
&#xD;
          -  Subjects should be either:&#xD;
&#xD;
               1. Treatment naïve from any antidiabetic treatment for at least 6 months prior to&#xD;
                  screening with a hemoglobin A1c (HBA1c) value between 7%-10%, inclusive.&#xD;
&#xD;
               2. On metformin alone with a HBA1c value between 7%-9%, inclusive, and willing to&#xD;
                  discontinue current metformin treatment for at least 2 weeks prior to study and&#xD;
                  during the duration of the study. See Section 9.10.1 for monitoring during 2 week&#xD;
                  washout.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subject is of childbearing potential, is pregnant (as based on test results) or&#xD;
             is breast feeding.&#xD;
&#xD;
          -  Male subjects should ensure use of condom and spermicide from dosing until 12 weeks&#xD;
             after dosing.&#xD;
&#xD;
          -  Male subjects must agree not to donate sperm from dosing until 12 weeks after dosing.&#xD;
&#xD;
          -  Any history of drug abuse.&#xD;
&#xD;
          -  History of alcohol addiction during the 2 years prior to Day 1.&#xD;
&#xD;
          -  History or current evidence, as determined by the Investigator, of psychiatric or&#xD;
             emotional problems which would invalidate giving informed consent or limit the ability&#xD;
             of the subject to comply with study requirements.&#xD;
&#xD;
          -  History or current alcoholic or non-alcoholic liver disease or liver steatosis.&#xD;
&#xD;
          -  History of neuropathy.&#xD;
&#xD;
          -  Subjects with QTcF interval duration &gt;450 msec obtained from the ECG taken at&#xD;
             screening, after at least 10 minutes of quiet rest in a supine position.&#xD;
&#xD;
          -  Subjects with a family history of long QT syndrome.&#xD;
&#xD;
          -  Subjects with any history of arrhythmia.&#xD;
&#xD;
          -  Significant blood donation or significant blood loss within the 56 days before Day -1.&#xD;
&#xD;
          -  Plasma donation within 7 days before Day -1.&#xD;
&#xD;
          -  Participation in another investigational new drug research study within the 30 days&#xD;
             before Day 1.&#xD;
&#xD;
          -  Use of tobacco products or nicotine-containing products (including smoking cessation&#xD;
             aids, such as gums or patches) within the 6 months before Day 1.&#xD;
&#xD;
          -  Relationship of the subject to the Investigator, any sub-investigator, pharmacist,&#xD;
             study coordinator, or other staff directly involved in the conduct of the study, or&#xD;
             employment by the Sponsor or contract research organization participating in the&#xD;
             study.&#xD;
&#xD;
          -  Familial relationship of the subject to any subjects previously or currently enrolled&#xD;
             in the study.&#xD;
&#xD;
          -  Screening laboratory values outside the range of normal values that are deemed&#xD;
             clinically significant by the Investigator. Liver function tests (AST, ALT, total&#xD;
             bilirubin, and lactate dehydrogenase [LDH]) must be at or below the ULN. If a subject&#xD;
             has a non-clinically significant high abnormal reading for one or more of the liver&#xD;
             function tests on the screening lab test, the test may be repeated once. If the lab&#xD;
             test results are normal on the repeat test, he/she may be enrolled provided the Day -1&#xD;
             lab test results are also normal.&#xD;
&#xD;
          -  Hemoglobin levels below the lower limit of normal of the clinical laboratory's&#xD;
             reference range at the screening visit.&#xD;
&#xD;
          -  Enrollment in a prior dose cohort of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2013</study_first_posted>
  <last_update_submitted>May 24, 2013</last_update_submitted>
  <last_update_submitted_qc>May 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

